Introduction
Immunology research is in a constant state of flux with new cell types being described on a regular basis. While most rheumatologists are familiar with the role that "T cell cytokines" such as tumor necrosis factor (TNF), interferon-g (IFNg), and interleukin-17A (IL-17A) play in the pathogenesis of rheumatic diseases, what many may not know is that an array of innate counterparts to the conventional T cells have recently been discovered that are capable of rapidly producing these same effector cytokines. These innate counterparts include g/d T cells, invariant natural killer (iNK) cells, mucosa-associated invariant T (MAIT) cells, and innate lymphoid cells (ILCs). An insightful overview of g/d T cells, iNK cells, and MAIT cells in rheumatic disease has recently been published (1) ; therefore, the current review focuses on ILCs. Strikingly, some of the ILCs have only recently been discovered, in part due to their relative scarcity in peripheral blood, and their presence in numerous organs of the human body has subsequently been described. In this review, we provide the newest insights into the potential role of ILCs in the field of rheumatology and provide recommendations for future ILC research that will help to promote our understanding of rheumatic diseases even further.
Essential background on recently discovered ILCs
ILCs as innate counterparts to T cells. Considerable phenotypic and functional overlap exists between ILCs and Th cells, yet there are important differences in activation pathways and tissue localization enabling distinct roles in inflammation. The priming of Th cells requires the recognition of peptide-loaded major histocompatibility complex (MHC) class II molecules provided by professional antigen-presenting cells such as dendritic cells (DCs). In contrast, ILCs do not express rearranged antigen receptors capable of recognizing antigens in a major histocompatibility complex. Activation of ILCs is instead mediated by a wide array of soluble mediators and stress molecules released and expressed by immune and stromal cells. In further contrast to Th cells, ILCs are continuously present at the peripheral barrier tissues in the body, readily able to produce the first waves of cytokine production upon damage or infection and to strongly shape the ensuing immune response (2) . From an evolutionary point of view, the comparable role of ILCs and T cells shows apparent redundancy (3) , and while ILC depletion in humans may not be critical for survival (4) , ILCs can contribute to the pathogenesis of many diseases (for review, see ref. 5) .
Conventional NK cells fall within the overarching group of ILCs but are genealogically different from the more recently identified "helper-like" ILCs, which are covered in this review. While the major function of conventional NK cells is inducing cytotoxicity, all other ILCs lack classic cytotoxicity-inducing capacity, and therein lies the distinction between "cytotoxic" and "helperlike" ILCs. Helper-like ILCs are defined by the presence of lymphoid morphology, expression of CD127 (IL-7 receptor a-chain [IL-7Ra]), and lack of lineage markers that are present on other cells (for instance, DCs or T cells). ILCs can be further classified into group 1 (ILC1s), group 2 (ILC2s), and group 3 (ILC3s), which to a great extent mimics the nomenclature that is used for the Th cell groups Th1, Th2, and Th17/Th22, respectively (6) . An overview of ILCs and their T cell counterparts is shown in Figure 1 .
ILC development. Helper-like ILCs are proposed to develop from a "common helper ILC precursor" or CHILP. Various transcription factors are involved in the differentiation of earlier precursors into CHILP. In mice, Id2, NFIL3, and Tox are crucial for the occurrence of all ILCs, while Runx3 is required for the normal development of ILC1s and ILC3s by regulating expression of retinoic acid receptor-related orphan nuclear receptor gt (RORgt) and aryl hydrocarbon receptor (AHR) (7) (8) (9) . Promyelocytic leukemia zinc-finger protein (PLZF) is a key transcription factor that is required for (most) helper-like ILCs to develop, while PLZF is not needed for conventional NK cell development (10) . Studies in mice have also taught us that the transcription factor GATA-3, the prototypical transcription factor of ILC2s, may also be important for the development and function of other ILC groups (11) . In mice, GATA-3 is necessary for development of IL-7Ra-expressing ILCs and homeostasis of ILC3s (12) . In summary, the balance among the 3 key transcription factors Figure 1 . Innate lymphoid cells (ILCs) and their T cell counterparts. Effector functions of ILCs overlap greatly with those of their T cell counterparts. ILCs induce a rapid, innate response (left) that is followed by a slower, adaptive response in T cells (right) targeting the same pathogens. Upstream factors that determine the effector cytokines produced by ILCs and T cells also show considerable overlap. For instance, interleukin-23 (IL-23) is a cytokine involved in the polarization of Th17 cells and is also known to enhance the production of effector cytokines by group 3 ILCs (ILC3s). cNK 5 conventional natural killer; IFNg 5 interferon-g; CTL 5 cytotoxic T lymphocyte; MHC 5 major histocompatibility complex; TNF 5 tumor necrosis factor; TSLP 5 thymic stromal lymphopoietin; PGD 2 5 prostaglandin D 2 .
RORgt, GATA-3, and T-bet determines the fate of ILCs in mice (5, 11, 13) . IL-7R signaling not only drives proliferation of ILC3s in mice and humans (4, 14) , but also stabilizes the ILC3 phenotype in adult mice (15) .
The current model of ILC development, depicted in Figure 2 , stems from murine data and may not fully mimic the process in humans. A recent review has critically summarized the data on ILC development in humans (16) , but a full developmental scheme for ILCs in humans is still lacking. We do know that human CD341 hematopoietic progenitor cells can, under specific culture conditions, give rise to ILCs (17) (18) (19) . One group has detected human ILC progenitors in the tonsil and gut lamina propria that developed preferentially into ILC3s when cultured with stem cell factor and AHR signaling, while culture conditions with IL-15 favored the development of conventional NK cells (17) . More recently, a similar progenitor population expressing RORgt and Id2 was identified that in vitro gave rise to all ILC subsets, including conventional NK cells. These ILC progenitors did not develop into other leukocyte lineages and were found exclusively in secondary lymphoid tissues (18) . Uncovering the stages of ILC development in humans remains a challenge in the field (16) .
ILC subsets. The system of ILC subset classification is based on their developmental pathways, key transcription factors, and function in the form of signature cytokines being produced (6) . Briefly, ILC1s express the transcription factor T-bet and produce IFNg; ILC2s express the transcription factor GATA-3 and produce IL-4, IL-5, and IL-13; and ILC3s express the transcription factor RORgt and produce IL-17A Figure 2 . Development and classification of innate lymphoid cells (ILCs). ILCs develop from the common lymphoid progenitor (CLP), which also gives rise to T cells. The development of the a4b7 integrin-expressing lymphoid progenitor (aLP) is dependent on 3 key transcription factors: NFIL3, Id2, and Tox. After this point, the development splits into natural killer cell precursors (NKP) and a common helper ILC precursor (CHILP), the latter being critically dependent on the transcription factor promyelocytic leukemia zinc finger protein (PLZF). Interleukin-15 (IL-15) is necessary for group 1 ILC (ILC1) development and IL-7 is necessary for ILC2 and ILC3 development. The CHILP gives rise to the 3 helper-like ILCs, each characterized by key transcription factors, namely T-bet, GATA-3, and retinoic acid receptor-related orphan nuclear receptor gt (RORgt) for ILC1s, ILC2s, and ILC3s, respectively. The current model of ILC development, depicted in the figure, stems from murine data. It should be noted that alternate developmental pathways may be possible in humans. For instance, lymphoid tissue inducers, a subset of ILC3s important for lymphoid neogenesis, may not follow the depicted developmental program. In addition, a recent study on ILC progenitors from human secondary lymphoid tissues revealed that a common RORgt-expressing ILC progenitor, probably upstream of the CHILP, was capable of giving rise to all ILCs and that all human ILCs, including conventional natural killer cells (cNK), still express RORgt to some extent (18) . Eomes 5 eomesodermin; AHR 5 aryl hydrocarbon receptor.
and/or IL-22. Human ILC subsets can be distinguished by the expression of specific cell surface markers (Table  1) . Natural cytotoxicity receptors are activating receptors best studied in the context of triggering conventional NK cells, when tumor and virus-infected cells up-regulate their ligands (many of which are still unknown). The natural cytotoxicity receptors include natural killer p30 (NKp30), NKp44 (only expressed in humans), and NKp46, which are also expressed by certain ILCs (20) , as will be discussed below.
ILC1s. ILC1s have been proposed to include conventional NK cells and CD1271 and CD1031 ILCs. Although conventional NK cells and ILC1s share many features (e.g., IFNg production), it is becoming clear that these 2 subsets have different progenitors as well as unique tissue distributions and functions (13, 19) . ILC1s have been found in intestinal mucosa, salivary gland, liver, and the female reproductive tract; there is a relative paucity of them in blood and lymphoid structures (21, 22) . On the other hand, conventional NK cells can make up to 15% of peripheral blood lymphocytes, and substantial numbers of them are present in lymphoid structures. ILC1s are thought to differ from conventional NK cells in that they lack expression of eomesodermin and do not exert cytolytic activity. Overall, ILC1s are a diverse group consisting of subsets that vary depending on their tissue microenvironment and the context of their circumstances (8) . For example, small intestine intraepithelial ILC1s have been characterized that did express eomesodermin (23) , while mouse ILC1s from salivary glands are capable of TRAIL-mediated cytotoxicity (24) . ILC1s have been suggested to rely on the cytokines IL-15, IL-12, and IL-18, and they produce copious amounts of IFNg and TNF. ILC1s protected mice from infection with Clostridium difficile and Toxoplasma gondii in 2 different infection models, and the ILCs constituted the (early) majority of IFNg-producing cells (13, 25) . Judging from those studies, the protective role of ILC1s against infections is important. However, exaggerated or insufficient immune responses by ILC1s might lead to immunopathology.
ILC2s. Consistent with Th2 cells, the transcription factor GATA-3 is the prototypical element required for the development, maintenance, and function of ILC2s. ILC2s are found in increased numbers in the lung, skin, and adipose tissue. They respond to cytokines such as epithelial cell-derived IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) by producing allergyand fibrosis-related cytokines, such as IL-4, IL-9, and IL-13. Unlike the other ILCs, ILC2s express the prostaglandin D 2 (PGD 2 ) receptor chemoattractant receptorlike molecule expressed on Th2 cells (CD294). PGD 2 induces the migration of ILC2s and potentiates their cytokine production (21) . For instance, ILC2s express NKp30, which responds to keratinocyte membraneexpressed B7-H6, leading to the production of IL-13, and skin from patients with atopic dermatitis expressed increased levels of B7-H6 (26) . ILC2s have diverse functions; they have been shown to promote immunity against extracellular parasites (27) , induce tissue repair by producing amphiregulin (28) , and promote beige fat and reduce insulin resistance (29) . However, deleterious roles of ILC2s have also been described. They are associated with allergies, asthma, and atopic dermatitis. In addition, ILC2s were required for the occurrence of fibrosis in a mouse model of hepatic fibrosis (30) . ILC3s. ILC3s are developmentally dependent on expression of the nuclear hormone receptor RORgt (31, 32) , although in mature ILC3s, this receptor is dispensable for survival and antimicrobial functionality (33) . Several subsets of ILC3s have been identified based on function and surface marker expression. The prototypical ILC3s are the lymphoid tissue inducers. These cells are present during fetal development in mice and humans and are responsible for initiation and organization of secondary lymphoid tissues (34) (35) (36) . Lymphoid tissue inducers interact with stromal and endothelial cells at sites of lymphoid organ development (37, 38) and by induction of chemokines and adhesion molecules initiate a cascade of well-described events culminating in the formation of lymph nodes and Peyer's patches (39) .
After birth and throughout adulthood, 2 additional ILC3 subsets are present, characterized by the mutually exclusive expression of the natural cytotoxicity receptor NKp46 and the chemokine receptor CCR6 (40, 41) . Both reside within secondary lymphoid organs as well as in mucosal tissues such as the intestines (36, (42) (43) (44) (45) . Functionally, ILC3s are characterized by the secretion of cytokines associated with Th17 cell immunity, including IL-22, granulocyte-macrophage colonystimulating factor (GM-CSF), and IL-17A (36, (42) (43) (44) (45) (46) . This cytokine profile and the location of ILC3s at barrier surfaces such as the intestines makes these cells form an integral part of the body's immediate antimicrobial immune response (40, (46) (47) (48) . ILC3s control epithelial production of antimicrobial peptides whose function is to prevent attachment and translocation of intestinal microorganisms (49) . In doing so, ILC3s boost the intestines' innate immunity and prevent bacterial dissemination in the wake of maturation of adaptive immunity (50) . Taken together, ILC3s are essential for the maintenance of gut homeostasis, for which they use several mechanisms.
Plasticity. It is important to acknowledge the plasticity of ILCs. For example, ILC3s have been demonstrated to differentiate into ILC1-like cells and vice versa under specific inflammatory conditions (51) (52) (53) (54) . Shifts between other ILCs have also been described (55) (56) (57) that help to explain the class, phenotype, and effector function of ILCs detected in diverse tissues under varying environmental circumstances, and plasticity should be taken into account when interpreting the frequency of ILC subsets in rheumatic disease. An overview of the environmental factors that have been shown to steer plasticity between ILC subsets in vitro is shown in Figure 3 .
Lessons from psoriasis and inflammatory bowel disease (IBD) Psoriasis. IL-22 and IL-17A are key players in the pathogenesis of psoriasis, and it has become evident that conventional T cells are not the only contributors to the production of these effector cytokines (58) . Although the NKp441 ILC3 population is very scarce in the peripheral blood, these cells represent a major proportion of the ILC population in healthy skin (58) (59) (60) , and numerous independent studies have shown that NKp441 ILC3s are even more abundant in skin and blood samples from patients with psoriasis (58) (59) (60) (61) (62) .
One very interesting finding pops up from studies of ILCs in psoriasis. The frequency of specifically NKp441 ILC3s in the unaffected skin of psoriasis patients is equal to if not higher than the frequency of NKp441 ILC3s in affected skin (58, 59) . This altered composition of ILCs in what would clinically appear to be unaffected skin of psoriasis patients raises the key question: are these NKp441 ILC3s pathogenic or protective? The most common interpretation is that NKp441 ILC3s in unaffected skin are prepositioned to initiate an inflammatory cascade (58) (59) (60) 62) . Animal models show that IL-22 causes skin lesions reminiscent of psoriasis, which supports the notion that NKp441 ILC3s are necessary and critical for this process (63, 64) . Under culture conditions, the cytokines IL-1b and IL-23 can shift ILC1 and NKp442 ILC3 populations toward NKp441 ILC3s (51, 62) . Recent gene expression profiling shows convincingly that "unaffected" psoriatic skin is quite different from skin of healthy individuals, with "already" significantly increased transcripts of IL-1b, IL-22, and IL-17 (65) . Taken together with the established genetic background of psoriasis patients that includes singlenucleotide polymorphisms (SNPs) in IL-23R (66), these findings might explain why ILC composition in unaffected skin of psoriasis patients is altered.
Our knowledge of ILC3 function mainly stems from mouse models or, in humans, from tonsil-or gutderived ILCs. It is known that NKp441 ILC3s from psoriatic skin lesions are capable of producing IL-22 to a much greater extent than IL-17A (62), but it would be an oversimplification to view IL-22 as purely pathogenic, since this cytokine has essential regulatory and regenerative functions (for review, see ref. In stark contrast to healthy skin, under homeostatic conditions the healthy gut is characterized by an abundant, protective NKp441 ILC3 population, which reciprocally shifts toward a predominance of ILC1s in IBD, meaning a significantly increased proportion of ILCs that secrete IFNg (23,51,52,69). Additionally, ILC3s from healthy gut mainly produce the homeostatic cytokine IL-22, while ILC3s in IBD also secrete proinflammatory IL-17A (70) . Animal models have also taught us that ILC3s can dampen pathogenic CD41 T cell responses (48) and that ILC3-derived IL-22 protects against colitis (71) and induces tolerance to commensal bacteria (47, 72) . The differential phenotype and function of ILCs in psoriasis versus IBD emphasizes that the outcome of ILC function (pathogenic versus protective) is highly dependent on the environment and tissue in which these cells are located.
Studies of ILCs in rheumatic disease
Psoriatic arthritis (PsA). ILCs have been found in increased numbers in synovial fluid from PsA patients (61). Synovial fluid from PsA patients and patients with rheumatoid arthritis (RA) showed an increase in frequency of ILC1s as compared to the frequency of ILC1s in peripheral blood, while the frequency of ILC2s was unaltered. Interestingly, only synovial fluid from PsA patients contained a major increase in NKp441 ILC3s, which distinguished the synovial compartment in PsA from that in RA. The increased presence of synovial fluid ILC3s also coincided with up-regulated expression of CCR6. In contrast, peripheral blood from PsA patients contained fewer CCR61 ILCs than did peripheral blood from healthy controls, and the frequency of CCR61 ILC3s was inversely related to disease activity measures, which could indicate specific targeting of these ILC3s to the joint in patients with PsA. ILC3s in synovial fluid from PsA patients were capable of IL-17A production, implicating their role in PsA pathogenesis (61) .
PsA has recently been thought of as a disease that starts at the enthesis with microtrauma and culminates in chronic inflammation. In contrast to mouse models of psoriasis and colitis, the role of ILCs has not been studied in experimental models of PsA. It is of particular interest to determine the relative importance of ILC3s and other innate lymphocytes, such as IL-17A-producing g/d T cells, as the latter have been demonstrated to be present in mouse models of enthesitis (73, 74) . Only one group has described the presence of ILC3s and ILC2s in nonrheumatic human spinal, anterior cruciate ligament, and Achilles tendon entheses, yet these data need to be published to be fully appreciated (75) . Future work should evaluate which activating/ inhibitory receptors are expressed by ILCs found in the joint and determine how their ligands expressed by tissue resident cells influence disease pathogenesis (76) (77) (78) (79) , for instance, by affecting production of proinflammatory cytokines by ILCs.
Ankylosing spondylitis (AS). AS is characterized by inflammatory back pain and axial new bone formation. Our current view of AS is that the cytokines TNF, IL-17, and IL-22 are critical drivers of its pathogenesis (73, 80, 81) . Animal models have further shown that innate counterparts to T cells can produce these cytokines, mimicking the clinical manifestations of AS (73, 74, 81) . ILC3s have been described in nonrheumatic enthesis (75) , and there is evidence of the increased presence of IL-22-producing NKp441 ILC3s in other tissues from AS patients. Ciccia et al described a cell subset consisting of CD561NKp441 cells, possibly ILC3s, to be the main producers of IL-22 in the gut of AS patients. In contrast, in Crohn's disease, CD41 T cells were the main producers of IL-22 (82) . In a follow-up study, Ciccia et al found an increased presence of a4b7 integrin-positive IL-171 and IL-221 ILC3s in the gut, blood, synovial fluid, and bone marrow (83) . The interesting hypothesis was put forward that gut-derived ILC3s might home to inflamed (sacroiliac) joints and contribute to the disease process by producing IL-17 and IL-22 (83) . A role for gut-derived immune cells is underscored by the transgenic HLA-B27 rat model of AS, in which the gut microbiome is necessary for the occurrence of disease (84, 85) . Consistent with PsA, a genetic background could enhance the role of ILC3s in the pathogenesis of AS. IL-23R, RUNX3, and MICA have all been linked to AS susceptibility (86) .
A recent study further demonstrated that PGE 2 , via the EP 4 receptor, potentiates gut ILC3 proliferation and IL-22 production (87). The effect of nonsteroidal antiinflammatory drugs on ILC3 proliferation and IL-22 production deserves investigation in the context of AS.
RA. RA is a disease driven by MHC class II molecules and adaptive immune responses, exemplified by the effectiveness of drugs targeting B cells and the interaction between costimulatory molecules and CD28 (CTLA-4Ig). ILCs have been implicated in supporting antibody production by B cells via diverse pathways, including lymphotoxin, CD40, and BAFF/APRIL signaling (88) . Adult ILC3s can sustain CD41 T cell memoryenhancing germinal center reactions and subsequent antibody production (89) . As discussed in the section on ILC3s, these cells are important in the development and homeostasis of secondary lymphoid tissue (82) . Under inflammatory conditions, so-called tertiary lymphoid structures can develop, which are germinal center-like structures that arise after birth at sites not originally in need of lymphoid structures.
This prompted a study to investigate if ILCs could be found in tertiary lymphoid structures of RA synovial tissue, but hardly any ILC3s were detected (90) . Another research group set out to characterize ILCs in inguinal lymph nodes in patients with preclinical RA (arthralgia patients positive for rheumatoid factor and/ or anti-citrullinated protein antibodies), patients with established RA, and healthy controls (91) . Although ILCs were sparsely present and there were no differences in total ILC numbers, it was found that in the lymph nodes of patients with preclinical RA, the ILC1/2 group (the study was hampered by not distinguishing between ILC1s and ILC2s) made up a larger proportion of the ILCs than in the lymph nodes of healthy controls. Interestingly, there was a shift in the ILC3 population from NKp442 ILC3s to NKp441 ILC3s in patients with established RA and a clear tendency toward fewer NKp442 ILC3s in patients with preclinical RA. Since NKp442 ILC3s are thought to be involved in maintaining secondary lymphoid tissue homeostasis (lymphoid tissue inducers), it was hypothesized that the loss of these cells may result in an autoimmune diseaseprone lymph node microenvironment (91).
The above-described paucity of ILC3s in RA synovial tertiary lymphoid structures (90) is consistent with the relative lack of ILC3s described in RA synovial fluid (61) and makes a role for ILC3s in the local RA disease process less likely. In contrast to ILC3s and ILC2s, ILC1s can readily be found in the RA synovial cavity, and the frequency of ILC1s there is strongly increased compared to the frequency of ILC1s in peripheral blood (61) . It appears that if ILCs play a role in local RA pathology, then ILC1s are the subset to look at and could contribute to the production of TNF and IFNg.
Sj€ ogren's syndrome (SS). ILCs have been identified in the salivary glands of mice (22, 24, 92) and humans (93) . The established role of ILCs in producing IL-22 and IL-17A, which are involved in the pathogenesis of primary SS (94), along with their presence at epithelial sites of the body poses ILCs as candidate contributors to the pathogenesis of primary SS. Specifically, it was shown that IL-22-producing NKp441 ILC3s were more abundant in the salivary glands of patients with primary SS than in the salivary glands of patients with sicca syndrome without SS, and that the frequency of the ILC3s was positively correlated with the lymphocytic focus score (93) . Additional studies will be needed to confirm these results and to further evaluate the function of ILC3s in salivary glands of patients with primary SS.
Three key areas deserve subsequent exploration in the setting of primary SS. First, ILCs from mice appear to be "tissue resident" in the salivary gland, meaning that they are barely replenished from circulating (precursor) ILCs that would subsequently migrate into the salivary gland (22, 92) . Second, the histopathology of SS is marked by the formation of tertiary lymphoid structures in salivary glands, which suggests the involvement of ILCs (36, 95) . Finally, SNPs in NKp30 that cause decreased expression of this receptor are less common in patients with primary SS, and, indeed, patients with primary SS have increased expression of NKp30 on conventional NK cells (96) . Helper-like ILCs can also express this receptor, and it is known that the ligand for NKp30, namely B7-H6, is expressed by salivary gland epithelial cells (96) . Taken together, these observations highlight the potential role of ILCs in primary SS and justify future research.
Systemic lupus erythematosus (SLE). ILCs have been described in patients with SLE as part of a control cohort for a study on systemic sclerosis (SSc), and the frequency of ILC2s was found to be increased in their circulation compared to that in healthy controls (97) . The noted elevated frequency of ILC2s is difficult to reconcile with the established effect of IFNs of decreasing ILC survival and function. SLE is clearly marked by an IFN signature (98) , yet studies in mice have shown that ILC3s undergo CD95/FasL-mediated apoptosis following the production of type I IFNs by plasmacytoid DCs (99) . Similarly, type I IFNs also increase cell death and decrease cytokine production by ILC2s (100).
Patients with SLE are prone to develop skin lesions (e.g., butterfly rash) following sunlight exposure (ultraviolet B) that induces excessive keratinocyte apoptosis (101) . ILCs are important in skin homeostasis, and this function is mediated by production of IL-22, a key cytokine that helps prevent keratinocyte damage (102, 103) . In this context, the (protective) role of IL-22-producing ILCs in epithelial homeostasis is an interesting avenue for investigation that could shed light on some of the cutaneous manifestations of the disease (104) .
SSc. SSc is marked by low-grade inflammation, vascular injury, and subsequent fibrosis of skin and internal organs. In a recent study, ILC2s were present in markedly increased numbers in the skin and blood of SSc patients. Numbers of ILC2s were elevated the most in patients with diffuse cutaneous SSc and correlated with the modified Rodnan skin thickness score (97, 105) . In light of the IFN signature (which is strongest in early and nonfibrotic SSc [106] ) and the suppressive effect of IFN on ILC2s (100), the increased numbers of ILC2s in more advanced stages of the disease is noteworthy (97) . The increased presence of ILC2s in SSc was not found in another study that compared 38 clinically undefined SSc patients with matched healthy controls (107) . It is unclear why there was such a difference in outcome between the 2 studies, but different methodologies (e.g., different cell markers and gating strategy used) could help explain the discrepancy.
With regard to the occurrence of fibrosis in SSc, the ILC2 subset is of particular interest. In mice, ILC2s were required for the occurrence of hepatic fibrosis, and IL-13 released by ILC2s was sufficient for collagen deposition in a mouse model of pulmonary fibrosis (30, 108) . ILC2s are activated, start producing cytokines (e.g., IL-13), and proliferate upon exposure to epithelial alarmin cytokines, such as IL-25, IL-33, and TSLP, all of which are found to be elevated in SSc (109) . ILC2-derived IL-13 induces collagen deposition from fibroblasts and differentiates macrophages toward a profibrotic phenotype (108) .
NKp441 ILC3s are an important source of IL-17A in skin inflammation, and IL-17A has been implicated in the generation of pulmonary and skin fibrosis (110) . In patients with SSc, the NKp441 ILC3 population was slightly increased in blood, while the NKp442 ILC3 population was decreased compared to that in healthy controls (107) . In addition, the same study found an increase in CD41 ILC1s, which were potent producers of TNF and GM-CSF, in the peripheral blood of SSc patients (107) . Future studies should examine the presence and function of ILCs at affected sites, such as the skin, to better understand their potential contribution to SSc.
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Conclusions
Over the past few years, it has become clear that ILCs play a pivotal role in orchestrating the first waves of the immune response in human tissue upon receiving danger signals, thereby contributing toward effective clearance of the initiating event. On the other hand, numerous studies have shown the relevance of ILCs in upholding tissue homeostasis. Clear evidence of this balancing act has been well studied in skin and gut disease, yet an overview of the contribution of ILCs to rheumatic disease has been lacking. In this review, we provide a comprehensive overview of the recent research that has been performed on helper-like ILCs in rheumatic diseases ( Table 2 ). Recent reports have begun to shed light on ILC aberrations in patients with IBD-associated arthritis (111) and antineutrophil cytoplasmic antibody-associated vasculitis (112) . Many other rheumatic diseases, such as Behçet's disease and reactive arthritis, await and deserve further exploration into the role of ILCs, and more work is needed on the diseases highlighted in this review.
We believe that future work should focus on 3 key issues. At first, due to the rarity of ILCs, our knowledge of these cells is largely based on flow cytometric phenotyping. Hence, we encourage the ILC field to adhere to the established framework for ILC gating to improve comparability between studies and between different clinical conditions as well as to use standardized measures before and after initiation of therapeutic intervention. Second, the low frequency of ILCs challenges our ability to isolate ILCs from human tissues for the purpose of functional assays. For instance, the culturing of ILCs to focus on their functional roles in health and disease poses challenges that hinder development of drugs to target pathologic processes that they orchestrate. Until now, our current knowledge of ILC development and function has been mainly based on experimental models, which leaves its relevance for humans to be determined. The use of alternative, novel techniques that give an understanding of human ILC function and development (e.g., single-cell sequencing [113, 114] ) should therefore be exploited further. Finally, strategies aimed at targeting ILC pathology by blocking their developmental fate, plasticity, and/ or effector function deserve further investigation (115) . Do therapies targeting the IL-23/IL-17 axis given to patients with psoriatic skin disease also halt aberrant ILC function in the joint or enthesis, preventing the transition toward concomitant joint disease? If this hypothesis holds true, we may go on to apply similar ways of delivering preventative medicine to patients with other rheumatic diseases, shifting our focus away from targeting the chronic effects of immune-mediated disease and toward disease interception, possibly by tackling the ILCs.
